Bridgepoint agrees to buy Waldencast’s Obagi Medical skincare business

Waldencast

Waldencast

WALD

0.00
  • Bridgepoint agreed to acquire Obagi Medical from Waldencast, taking control of the dermatological skincare and aesthetics brand founded in 1988.
  • Obagi operates across North America, Europe, Asia, and the Middle East through dermatologists and other healthcare professionals.
  • Waldencast founders Michel Brousset and Hind Sebti, joined by selected managers, will move to lead Obagi alongside Bridgepoint.
  • Waldencast expects Felipe Dutra to become executive chairman to oversee the transition, shifting focus toward Milk Makeup.
  • The deal is expected to close in the third quarter of 2026, subject to customary closing conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgepoint Group plc published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.